Those with low IL6R expression exhibited less mature myeloid cell infiltration and better overall survival (OS), whereas those with high IL6 levels, high IL6R expression, and high infiltration of tumor-associated CD163+ myeloid cells were associated with poor clinical outcomes [103]. The gene discussed is IL6R; the disease is neoplasm.